Canada Markets open in 8 hrs 37 mins
  • S&P/TSX

    21,077.35
    -85.30 (-0.40%)
     
  • S&P 500

    4,701.21
    +14.46 (+0.31%)
     
  • DOW

    35,754.75
    +35.32 (+0.10%)
     
  • CAD/USD

    0.7896
    -0.0010 (-0.1263%)
     
  • CRUDE OIL

    73.01
    +0.65 (+0.90%)
     
  • BTC-CAD

    63,164.89
    -1,169.46 (-1.82%)
     
  • CMC Crypto 200

    1,305.70
    +0.58 (+0.04%)
     
  • GOLD FUTURES

    1,787.30
    +1.80 (+0.10%)
     
  • RUSSELL 2000

    2,271.71
    +17.92 (+0.80%)
     
  • 10-Yr Bond

    1.5090
    0.0000 (0.00%)
     
  • NASDAQ futures

    16,377.00
    -15.25 (-0.09%)
     
  • VOLATILITY

    19.90
    -1.99 (-9.09%)
     
  • FTSE

    7,337.05
    -2.85 (-0.04%)
     
  • NIKKEI 225

    28,774.76
    -85.86 (-0.30%)
     
  • CAD/EUR

    0.6964
    -0.0003 (-0.04%)
     

2 Upcoming FDA Approval Decisions That Investors Should Really Watch

·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

In this Motley Fool Live video recorded on Oct. 13, Fool contributors Keith Speights and Brian Orelli discuss two upcoming U.S. Food and Drug Administration (FDA) approval decisions that investors should keep an eye on. Keith Speights: Brian, on another note, the FDA is set to make several important approval decisions in the fourth quarter. Brian Orelli: Biomarin (NASDAQ: BMRN) has one coming up on Nov. 20.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting